Glaucoma News and Research

Latest Glaucoma News and Research

ACADIA third quarter revenues decrease to $584,000

9 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

Laser therapy to turn brown eyes blue

A laser treatment developed by Stroma Medical's Dr. Gregg Homer takes only 20 seconds to perform but can turn brown eyes into blue ones permanently.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.

3 Nov 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Older adults with glaucoma at increased risk of falls

Older adults with glaucoma are at increased risk of falls resulting in injury, reports a study in the November issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

24 Oct 2011

Macular degeneration drug may cause increased IOP

Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that will be presented at the American Academy of Ophthalmology in Orlando.

24 Oct 2011

Carl Zeiss Meditec to showcase new clinical and productivity tools at AAO annual meeting

Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.

24 Oct 2011

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function.

12 Oct 2011

UB scientists discover promising new drug target for Alzheimer's

A tiny piece of a critical receptor that fuels the brain and without which sentient beings cannot live has been discovered by University at Buffalo scientists as a promising new drug target for Alzheimer's and other neurodegenerative diseases.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

10 Oct 2011

Logistic regression models identify risk factors for open angle glaucoma

Early detection and diagnosis of open angle glaucoma important so that treatment can be used in the early stages of the disease developing to prevent or avoid further vision loss.

7 Oct 2011

DMEI dedicates new $46M research and clinical facility

Officials from the Dean McGee Eye Institute today announced the dedication of the Institute's new $46 million, five-story, 78,000-square-foot, world-class research and clinical facility.

1 Oct 2011

Many Canadians are not screening for glaucoma earlier, finds study

Glaucoma is the second leading cause of blindness worldwide. Although it can be treated, new research shows Canadians may not be doing enough to protect themselves. According to a new study by Lawson Health Research Institute's Dr. Cindy Hutnik, many Canadian glaucoma patients are not screened until the disease has reached moderate or advanced stages.

30 Sep 2011

Cocaine use linked to increased risk of open-angle glaucoma

A study of the 5.3 million men and women seen in Department of Veterans Affairs outpatient clinics in a one-year period found that use of cocaine is predictive of open-angle glaucoma, the most common type of glaucoma.

30 Sep 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

26 Sep 2011

IRIDEX licenses rights to Ocunetics' intellectual property

IRIDEX Corporation today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company based in Alamo, California. Ocunetics develops procedure-enabling medical devices that are intended to increase surgeons' efficiency, while improving case predictability for ophthalmic surgeries.

21 Sep 2011

Glaucoma News and Research

Latest Glaucoma News and Research

ACADIA third quarter revenues decrease to $584,000

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Laser therapy to turn brown eyes blue

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Older adults with glaucoma at increased risk of falls

Macular degeneration drug may cause increased IOP

Carl Zeiss Meditec to showcase new clinical and productivity tools at AAO annual meeting

Positive top line results from Shire's LDX phase III study on ADHD

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

UB scientists discover promising new drug target for Alzheimer's

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Logistic regression models identify risk factors for open angle glaucoma

DMEI dedicates new $46M research and clinical facility

Many Canadians are not screening for glaucoma earlier, finds study

Cocaine use linked to increased risk of open-angle glaucoma

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

IRIDEX licenses rights to Ocunetics' intellectual property

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Glaucoma News and Research

Latest Glaucoma News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in